N‐glycosylation of the SARS‐CoV‐2 spike protein at Asn331 and Asn343 is involved in spike‐ACE2 binding, virus entry, and regulation of IL‐6
The coronavirus disease 2019 (COVID‐19) pandemic is an ongoing global public health crisis. The causative agent, the SARS‐CoV‐2 virus, enters host cells via molecular interactions between the viral spike protein and the host cell ACE2 surface protein. The SARS‐CoV‐2 spike protein is extensively deco...
Saved in:
Published in | Microbiology and immunology Vol. 68; no. 5; pp. 165 - 178 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
01.05.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The coronavirus disease 2019 (COVID‐19) pandemic is an ongoing global public health crisis. The causative agent, the SARS‐CoV‐2 virus, enters host cells via molecular interactions between the viral spike protein and the host cell ACE2 surface protein. The SARS‐CoV‐2 spike protein is extensively decorated with up to 66 N‐linked glycans. Glycosylation of viral proteins is known to function in immune evasion strategies but may also function in the molecular events of viral entry into host cells. Here, we show that N‐glycosylation at Asn331 and Asn343 of SARS‐CoV‐2 spike protein is required for it to bind to ACE2 and for the entry of pseudovirus harboring the SARS‐CoV‐2 spike protein into cells. Interestingly, high‐content glycan binding screening data have shown that N‐glycosylation of Asn331 and Asn343 of the RBD is important for binding to the specific glycan molecule G4GN (Galβ−1,4 GlcNAc), which is critical for spike‐RBD‐ACE2 binding. Furthermore, IL‐6 was identified through antibody array analysis of conditioned media of the corresponding pseudovirus assay. Mutation of N‐glycosylation of Asn331 and Asn343 sites of the spike receptor‐binding domain (RBD) significantly reduced the transcriptional upregulation of pro‐inflammatory signaling molecule IL‐6. In addition, IL‐6 levels correlated with spike protein levels in COVID‐19 patients' serum. These findings establish the importance of RBD glycosylation in SARS‐CoV‐2 pathogenesis, which can be exploited for the development of novel therapeutics for COVID‐19. |
---|---|
AbstractList | The coronavirus disease 2019 (COVID‐19) pandemic is an ongoing global public health crisis. The causative agent, the SARS‐CoV‐2 virus, enters host cells via molecular interactions between the viral spike protein and the host cell ACE2 surface protein. The SARS‐CoV‐2 spike protein is extensively decorated with up to 66 N‐linked glycans. Glycosylation of viral proteins is known to function in immune evasion strategies but may also function in the molecular events of viral entry into host cells. Here, we show that N‐glycosylation at Asn331 and Asn343 of SARS‐CoV‐2 spike protein is required for it to bind to ACE2 and for the entry of pseudovirus harboring the SARS‐CoV‐2 spike protein into cells. Interestingly, high‐content glycan binding screening data have shown that N‐glycosylation of Asn331 and Asn343 of the RBD is important for binding to the specific glycan molecule G4GN (Galβ−1,4 GlcNAc), which is critical for spike‐RBD‐ACE2 binding. Furthermore, IL‐6 was identified through antibody array analysis of conditioned media of the corresponding pseudovirus assay. Mutation of N‐glycosylation of Asn331 and Asn343 sites of the spike receptor‐binding domain (RBD) significantly reduced the transcriptional upregulation of pro‐inflammatory signaling molecule IL‐6. In addition, IL‐6 levels correlated with spike protein levels in COVID‐19 patients' serum. These findings establish the importance of RBD glycosylation in SARS‐CoV‐2 pathogenesis, which can be exploited for the development of novel therapeutics for COVID‐19. The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global public health crisis. The causative agent, the SARS-CoV-2 virus, enters host cells via molecular interactions between the viral spike protein and the host cell ACE2 surface protein. The SARS-CoV-2 spike protein is extensively decorated with up to 66 N-linked glycans. Glycosylation of viral proteins is known to function in immune evasion strategies but may also function in the molecular events of viral entry into host cells. Here, we show that N-glycosylation at Asn331 and Asn343 of SARS-CoV-2 spike protein is required for it to bind to ACE2 and for the entry of pseudovirus harboring the SARS-CoV-2 spike protein into cells. Interestingly, high-content glycan binding screening data have shown that N-glycosylation of Asn331 and Asn343 of the RBD is important for binding to the specific glycan molecule G4GN (Galβ-1,4 GlcNAc), which is critical for spike-RBD-ACE2 binding. Furthermore, IL-6 was identified through antibody array analysis of conditioned media of the corresponding pseudovirus assay. Mutation of N-glycosylation of Asn331 and Asn343 sites of the spike receptor-binding domain (RBD) significantly reduced the transcriptional upregulation of pro-inflammatory signaling molecule IL-6. In addition, IL-6 levels correlated with spike protein levels in COVID-19 patients' serum. These findings establish the importance of RBD glycosylation in SARS-CoV-2 pathogenesis, which can be exploited for the development of novel therapeutics for COVID-19. |
Author | Lu, Jinqiao Anderson, Blake Luo, Shuhong Huang, Steven Zhang, Benyue Mao, Yinging Dash, Sabyasachi Shajahan, Asif Tang, Hao Yen, Haw‐Han Jones, Valerie S. Pepi, Lauren Das, Tuhin Xie, Shehuo Huang, Ruo‐Pan Azadi, Parastoo Fang, Jianmin Huang, Gordon F. |
Author_xml | – sequence: 1 givenname: Tuhin orcidid: 0000-0001-8202-0838 surname: Das fullname: Das, Tuhin organization: RayBiotech Life Inc – sequence: 2 givenname: Shuhong orcidid: 0000-0002-9058-4833 surname: Luo fullname: Luo, Shuhong organization: RayBiotech Guangzhou Co. Ltd. Guangzhou – sequence: 3 givenname: Hao surname: Tang fullname: Tang, Hao organization: RayBiotech Guangzhou Co. Ltd. Guangzhou – sequence: 4 givenname: Jianmin surname: Fang fullname: Fang, Jianmin organization: RayBiotech Guangzhou Co. Ltd. Guangzhou – sequence: 5 givenname: Yinging orcidid: 0009-0004-2193-7983 surname: Mao fullname: Mao, Yinging organization: RayBiotech Life Inc – sequence: 6 givenname: Haw‐Han surname: Yen fullname: Yen, Haw‐Han organization: RayBiotech Life Inc – sequence: 7 givenname: Sabyasachi orcidid: 0000-0003-3966-9396 surname: Dash fullname: Dash, Sabyasachi organization: Center for Vascular Biology, Weill Cornell Medicine – sequence: 8 givenname: Asif orcidid: 0000-0002-4804-1130 surname: Shajahan fullname: Shajahan, Asif organization: Vaccine Research Center – sequence: 9 givenname: Lauren orcidid: 0000-0002-5740-4175 surname: Pepi fullname: Pepi, Lauren organization: Vaccine Research Center – sequence: 10 givenname: Steven surname: Huang fullname: Huang, Steven organization: RayBiotech Life Inc – sequence: 11 givenname: Valerie S. orcidid: 0000-0002-4204-9959 surname: Jones fullname: Jones, Valerie S. organization: RayBiotech Life Inc – sequence: 12 givenname: Shehuo surname: Xie fullname: Xie, Shehuo organization: RayBiotech Guangzhou Co. Ltd. Guangzhou – sequence: 13 givenname: Gordon F. surname: Huang fullname: Huang, Gordon F. organization: RayBiotech Life Inc – sequence: 14 givenname: Jinqiao surname: Lu fullname: Lu, Jinqiao organization: RayBiotech Life Inc – sequence: 15 givenname: Blake orcidid: 0000-0003-3237-9046 surname: Anderson fullname: Anderson, Blake organization: RayBiotech Life Inc – sequence: 16 givenname: Benyue orcidid: 0000-0002-3610-3517 surname: Zhang fullname: Zhang, Benyue organization: RayBiotech Life Inc – sequence: 17 givenname: Parastoo orcidid: 0000-0002-6166-9432 surname: Azadi fullname: Azadi, Parastoo organization: University of Georgia – sequence: 18 givenname: Ruo‐Pan orcidid: 0000-0002-5884-8026 surname: Huang fullname: Huang, Ruo‐Pan email: rhuang@raybiotech.com organization: Guangzhou Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38444370$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkEtOwzAURS0Eoh8YM0NeQFNsP-c3jKIClVqQKDCN8nGKIXWiOC3KjCUwYYOsBCeF4oF95XePLZ0ROlalEghdUDKlZl1R4J5FOKNTCpTRIzQ83ByjIQHPtmyHkAEaaf1KCHOZx0_RADzOObhkiL7uvj8-10Wblrot4kaWCpc5bl4EXgUPKzMLy2ezM6wr-SZwVZeNkArHDQ60AqA4VlkfOWCpsVS7stiJzIQ9YdggnDGcSJVJtZ7gnay3GgvV1O2kh2ux3v7_PF8YwjlDJ3lcaHH-e47R0_XsMby1Fvc38zBYWCn3GbVY4mdAiW0nxM0AIHac1MszN3FTwU0DXN_mwo49F2LXzr2OShgI40EIJ_NhjC7371bbZCOyqKrlJq7b6M-PKdj7wrssRHuYUxJ1-qNOdtTJjnr90XK-7AP8APneez0 |
CitedBy_id | crossref_primary_10_3390_life15020162 |
ContentType | Journal Article |
Copyright | 2024 The Authors. published by The Societies and John Wiley & Sons Australia, Ltd. 2024 The Authors. Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd. |
Copyright_xml | – notice: 2024 The Authors. published by The Societies and John Wiley & Sons Australia, Ltd. – notice: 2024 The Authors. Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd. |
DBID | 24P CGR CUY CVF ECM EIF NPM |
DOI | 10.1111/1348-0421.13121 |
DatabaseName | Wiley Online Library Open Access (Activated by CARLI) Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access (Activated by CARLI) url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1348-0421 |
EndPage | 178 |
ExternalDocumentID | 38444370 MIM13121 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: National Institutes of Health (NIH) funderid: R24GM137782‐01 – fundername: NIGMS NIH HHS grantid: R24 GM137782 – fundername: National Institutes of Health (NIH) grantid: R24GM137782-01 |
GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 123 1OC 24P 29M 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5HH 5LA 5RE 5VS 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 A8Z AAESR AAEVG AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCUV ABJNI ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACPOU ACPRK ACRPL ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AUFTA AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 C45 CAG COF CS3 D-E D-F DCZOG DIK DPXWK DRFUL DRSTM DU5 E3Z EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GODZA H.T H.X HF~ HGLYW HVGLF HZ~ J0M JSF JSH KQ8 LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MM. MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ O66 O9- OHT OIG OK1 OVD P2P P2W P2X P4D PQQKQ Q.N Q11 QB0 R.K RJT ROL RX1 RZJ SJN SUPJJ SV3 TEORI TKC TWZ UB1 V8K W8V W99 WBKPD WHG WIH WIK WIN WNSPC WOHZO WXSBR WYISQ X7M XG1 XOL XSB ZGI ZXP ZZTAW ~IA ~WT AAMMB AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CGR CUY CVF ECM EIF NPM OVT |
ID | FETCH-LOGICAL-c4921-2b9d31055b07d333a66c8fd7b7ce449237954e5a873a75f8c492b23e027ee6d93 |
IEDL.DBID | 24P |
ISSN | 0385-5600 |
IngestDate | Mon Jul 21 05:57:13 EDT 2025 Wed Jan 22 17:19:13 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | ACE2 COVID‐19 SARS‐CoV‐2 receptor‐binding domain spike protein N‐glycosylation IL‐6 |
Language | English |
License | Attribution 2024 The Authors. Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4921-2b9d31055b07d333a66c8fd7b7ce449237954e5a873a75f8c492b23e027ee6d93 |
Notes | Tuhin Das, Shuhong Luo, and Hao Tang contributed equally to this study. |
ORCID | 0000-0002-4204-9959 0000-0003-3237-9046 0000-0002-6166-9432 0000-0003-3966-9396 0000-0001-8202-0838 0009-0004-2193-7983 0000-0002-3610-3517 0000-0002-5740-4175 0000-0002-5884-8026 0000-0002-4804-1130 0000-0002-9058-4833 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1348-0421.13121 |
PMID | 38444370 |
PageCount | 14 |
ParticipantIDs | pubmed_primary_38444370 wiley_primary_10_1111_1348_0421_13121_MIM13121 |
PublicationCentury | 2000 |
PublicationDate | May 2024 |
PublicationDateYYYYMMDD | 2024-05-01 |
PublicationDate_xml | – month: 05 year: 2024 text: May 2024 |
PublicationDecade | 2020 |
PublicationPlace | Australia |
PublicationPlace_xml | – name: Australia |
PublicationTitle | Microbiology and immunology |
PublicationTitleAlternate | Microbiol Immunol |
PublicationYear | 2024 |
References | 2021; 6 2021; 21 2021; 20 2021; 4 2020; 20 2020; 383 2010; 169 2021; 128 2020; 181 2020; 182 2019; 15 2020; 369 2020; 588 2020; 16 2020; 15 2019; 18 2021; 384 2020; 584 2020; 11 2020; 146 2020; 367 2020; 10 2014; 40 2015; 7 2019; 145 2007; 15 2013; 9 2020; 18 2021; 35 2015; 23 2021; 13 2015; 25 2021; 31 2003; 348 2021; 12 2020; 2 2021; 433 2021; 118 2018; 92 2020; 28 2020; 116 2020; 26 2017 2020; 257 2012; 4 2022; 503 2016; 23 |
References_xml | – volume: 369 start-page: 330 issue: 6501 year: 2020 end-page: 333 article-title: Site‐specific glycan analysis of the SARS‐CoV‐2 spike publication-title: Science – volume: 20 start-page: 533 issue: 5 year: 2020 end-page: 534 article-title: An interactive web‐based dashboard to track COVID‐19 in real time publication-title: Lancet Infect Dis – volume: 20 year: 2021 article-title: Site‐specific N‐glycosylation characterization of recombinant SARS‐CoV‐2 spike proteins publication-title: Mol Cell Proteomics – volume: 12 year: 2021 article-title: The importance of glycans of viral and host proteins in enveloped virus infection publication-title: Front Immunol – volume: 4 start-page: 1011 issue: 6 year: 2012 end-page: 1033 article-title: Mechanisms of coronavirus cell entry mediated by the viral spike protein publication-title: Viruses – volume: 588 start-page: 682 year: 2020 end-page: 687 article-title: SARS‐CoV‐2 neutralizing antibody structures inform therapeutic strategies publication-title: Nature – volume: 11 year: 2020 article-title: Variations in SARS‐CoV‐2 spike protein cell epitopes and glycosylation profiles during global transmission course of COVID‐19 publication-title: Front Immunol – volume: 181 start-page: 281 issue: 2 year: 2020 end-page: 292 article-title: Structure, Function, and Antigenicity of the SARS‐CoV‐2 Spike Glycoprotein publication-title: Cell – volume: 18 start-page: 179 issue: 1 year: 2020 article-title: Emerging SARS‐CoV‐2 mutation hot spots include a novel RNA‐dependent‐RNA polymerase variant publication-title: J Transl Med – volume: 367 start-page: 1260 issue: 6483 year: 2020 end-page: 1263 article-title: Cryo‐EM structure of the 2019‐nCoV spike in the prefusion conformation publication-title: Science – volume: 348 start-page: 1953 issue: 20 year: 2003 end-page: 1966 article-title: A novel coronavirus associated with severe acute respiratory syndrome publication-title: N Engl J Med – volume: 2 issue: 2 year: 2020 article-title: SARS‐CoV‐2 and COVID‐19: Is interleukin‐6 (IL‐6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc publication-title: Cytokine: X – volume: 584 start-page: 443 issue: 7821 year: 2020 end-page: 449 article-title: Potently neutralizing and protective human antibodies against SARS‐CoV‐2 publication-title: Nature – start-page: 149 year: 2017 end-page: 158 – volume: 15 start-page: 346 issue: 6 year: 2019 end-page: 366 article-title: Glycosylation in health and disease publication-title: Nat Rev Nephrol – volume: 11 year: 2020 article-title: Comparative Review of SARS‐CoV‐2, SARS‐CoV, MERS‐CoV, and influenza A respiratory viruses publication-title: Front Immunol – volume: 28 start-page: 586 issue: 4 year: 2020 end-page: 601 article-title: Virus‐Receptor Interactions of Glycosylated SARS‐CoV‐2 Spike and Human ACE2 Receptor publication-title: Cell Host Microbe – volume: 169 start-page: 365 issue: 2 year: 2010 end-page: 374 article-title: Generation of VSV pseudotypes using recombinant ΔG‐VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines publication-title: J Virol Methods – volume: 146 year: 2020 article-title: The SARS‐CoV‐2 spike protein alters barrier function in 2D static and 3D microfluidic in‐vitro models of the human blood‐brain barrier publication-title: Neurobiol Dis – volume: 584 start-page: 437 issue: 7821 year: 2020 end-page: 442 article-title: Convergent antibody responses to SARS‐CoV‐2 in convalescent individuals publication-title: Nature – volume: 92 issue: 4 year: 2018 article-title: Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine‐Tuned for Enteric Infections publication-title: J Virol – volume: 25 start-page: 1323 issue: 12 year: 2015 end-page: 1324 article-title: Symbol Nomenclature for Graphical Representations of Glycans publication-title: Glycobiology – volume: 12 year: 2021 article-title: Interleukin‐6 Is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia publication-title: Front Immunol – volume: 7 start-page: 1700 issue: 4 year: 2015 end-page: 1725 article-title: Incorporation of spike and membrane glycoproteins into coronavirus virions publication-title: Viruses – volume: 182 start-page: 1284 issue: 5 year: 2020 end-page: 1294 article-title: The impact of mutations in SARS‐CoV‐2 spike on viral infectivity and antigenicity publication-title: Cell – volume: 4 start-page: 475 issue: 1 year: 2021 article-title: Human ACE2 receptor polymorphisms and altered susceptibility to SARS‐CoV‐2 publication-title: Commun Biol – volume: 31 start-page: 410 issue: 4 year: 2021 end-page: 424 article-title: Comprehensive characterization of N‐ and O‐ glycosylation of SARS‐CoV‐2 human receptor angiotensin converting enzyme 2 publication-title: Glycobiology – volume: 145 year: 2019 article-title: Production of pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting publication-title: J Vis Exp – volume: 118 issue: 19 year: 2021 article-title: Dual nature of human ACE2 glycosylation in binding to SARS‐CoV‐2 spike publication-title: Proc Natl Acad Sci – volume: 40 start-page: 785 year: 2014 end-page: 794 article-title: Viral Interactions with Glycans publication-title: Glycosci: Biol Med – volume: 23 start-page: 899 issue: 10 year: 2016 end-page: 905 article-title: Glycan shield and epitope masking of a coronavirus spike protein observed by cryo‐electron microscopy publication-title: Nat Struct Mol Biol – volume: 35 start-page: 3026 issue: 10 year: 2021 end-page: 3029 article-title: An evidence that SARS‐Cov‐2/COVID‐19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome‐dependent manner publication-title: Leukemia – volume: 384 start-page: 1564 issue: 16 year: 2021 end-page: 1565 article-title: Interleukin‐6 receptor inhibition in Covid‐19—cooling the inflammatory soup publication-title: N Engl J Med – volume: 15 start-page: 817 issue: 12 year: 2020 end-page: 822 article-title: Relationship between IL‐6 and COVID‐19: to be considered during treatment publication-title: Future Virol – volume: 503 year: 2022 article-title: The spike‐ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS‐CoV‐2 inhibitors and neutralizing antibodies publication-title: J Immunol Methods – volume: 18 start-page: 2348 issue: 12 year: 2019 end-page: 2358 article-title: Why glycosylation matters in building a better flu vaccine publication-title: Mol Cell Proteomics – volume: 369 start-page: 1261 issue: 6508 year: 2020 end-page: 1265 article-title: Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 publication-title: Science – volume: 13 start-page: 963 issue: 10 year: 2021 end-page: 968 article-title: A glycan gate controls opening of the SARS‐CoV‐2 spike protein publication-title: Nat Chem – volume: 128 start-page: 1323 issue: 9 year: 2021 end-page: 1326 article-title: SARS‐CoV‐2 spike protein impairs endothelial function via downregulation of ACE 2 publication-title: Circ Res – volume: 16 issue: 12 year: 2020 article-title: SARS‐CoV‐2 spike protein promotes IL‐6 trans‐signaling by activation of angiotensin II receptor signaling in epithelial cells publication-title: PLoS Pathog – volume: 383 start-page: 1813 issue: 19 year: 2020 end-page: 1826 article-title: Remdesivir for the treatment of Covid‐19—final report publication-title: N Engl J Med – volume: 181 start-page: 271 issue: 2 year: 2020 end-page: 280 article-title: SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor publication-title: Cell – volume: 584 start-page: 450 issue: 7821 year: 2020 end-page: 456 article-title: Potent neutralizing antibodies against multiple epitopes on SARS‐CoV‐2 spike publication-title: Nature – volume: 11 start-page: 11 year: 2020 article-title: Evaluation of neutralizing antibodies against highly pathogenic coronaviruses: a detailed protocol for a rapid evaluation of neutralizing antibodies using vesicular stomatitis virus pseudovirus‐based assay publication-title: Front Microbiol – volume: 9 start-page: 776 issue: 12 year: 2013 end-page: 784 article-title: Adaptive immune activation: glycosylation does matter publication-title: Nat Chem Biol – volume: 10 issue: 1 year: 2020 article-title: Analysis of the SARS‐CoV‐2 spike protein glycan shield reveals implications for immune recognition publication-title: Sci Rep – volume: 23 start-page: 630 issue: 10 year: 2015 end-page: 641 article-title: Sweet talk: protein glycosylation in bacterial interaction with the host publication-title: TIM – volume: 433 issue: 4 year: 2021 article-title: Subtle influence of ACE2 glycan processing on SARS‐CoV‐2 recognition publication-title: J Mol Biol – volume: 257 year: 2020 article-title: The bio‐mission of interleukin‐6 in the pathogenesis of COVID‐19: a brief look at potential therapeutic tactics publication-title: Life Sci – volume: 21 start-page: 337 issue: 6 year: 2021 end-page: 339 article-title: Is IL‐6 a key cytokine target for therapy in COVID‐19? publication-title: Nat Rev Immunol – volume: 6 start-page: 396 issue: 1 year: 2021 article-title: The glycosylation in SARS‐CoV‐2 and its receptor ACE2 publication-title: Signal Transduct Target Ther – volume: 116 start-page: 2207 issue: 14 year: 2020 end-page: 2215 article-title: SARS‐CoV‐2 infects and induces cytotoxic effects in human cardiomyocytes publication-title: Cardiovasc Res – volume: 15 start-page: 211 issue: 5 year: 2007 end-page: 218 article-title: Virus glycosylation: role in virulence and immune interactions publication-title: TIM – volume: 26 year: 2020 article-title: Serum interleukin‐6 concentrations and the severity of COVID‐19 pneumonia: a retrospective study at a single center in Bengbu City, Anhui Province, China, in January and February 2020 publication-title: Med Sci Monit – volume: 369 start-page: 643 issue: 6504 year: 2020 end-page: 650 article-title: Potent neutralizing antibodies from COVID‐19 patients define multiple targets of vulnerability publication-title: Science |
SSID | ssj0027284 |
Score | 2.3864574 |
Snippet | The coronavirus disease 2019 (COVID‐19) pandemic is an ongoing global public health crisis. The causative agent, the SARS‐CoV‐2 virus, enters host cells via... The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global public health crisis. The causative agent, the SARS-CoV-2 virus, enters host cells via... |
SourceID | pubmed wiley |
SourceType | Index Database Publisher |
StartPage | 165 |
SubjectTerms | ACE2 Angiotensin-Converting Enzyme 2 - metabolism Asparagine - metabolism COVID-19 - metabolism COVID-19 - virology COVID‐19 Glycosylation HEK293 Cells Humans IL‐6 Interleukin-6 - metabolism N‐glycosylation Polysaccharides - metabolism Protein Binding receptor‐binding domain SARS-CoV-2 - metabolism SARS-CoV-2 - physiology SARS‐CoV‐2 Spike Glycoprotein, Coronavirus - chemistry Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - metabolism spike protein Virus Internalization |
Title | N‐glycosylation of the SARS‐CoV‐2 spike protein at Asn331 and Asn343 is involved in spike‐ACE2 binding, virus entry, and regulation of IL‐6 |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1348-0421.13121 https://www.ncbi.nlm.nih.gov/pubmed/38444370 |
Volume | 68 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LSwMxEA6iCF7E91ty8OhK89hN9liKpRVbilrxtmw2iSzKVrpV6M2f4MU_6C9xktRavHkJgTBZyLyXmW8QOsu1KZKG5ZF2mQ54CB0pCJQhS5EGBMoWVLgG514_6Qz51UP8U03oemECPsT8h5vTDG-vnYLnql5QcsK4jEDkyAVhxLWSr7gGWwefT_ngN-eiMiBIyThyzn2G7uOKef5csOCCFsNU72faG2h9FiDiZuDoJloy1RZaDSMjp9vos__1_vH4PC1G9TSUseGRxRDF4dvmzS2ctUb3sFJcv5RPBnsYhrLC-QQ364oxgvNK-y1nuKxxWYF5ejMaNoECaJutS4pV6dtdzvFbOX6tsZ8_cu6Jx2F6_ezL3WugSHbQsH151-pEs9EKUcFTSiKqUs3cbEzVEJoxlidJIa0WShSGO8w2kcbcxLkULBexlY5KUWbgQY1JdMp20XI1qsw-wiKVxFLNDbeW29TmxKYJj4niBGxFag_QXnjX7CXgZ2RMcs6ZaBygwOD5wU9C4jiTOc5knjNZr9vzm8P_EhyhNQpBSChQPEbLk_GrOYEgYqJOvZjA2h_0vgHUgr-L |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8MwHA-iiF7E91tz8LjKkvzbpMcxlE23IW6Kt9I2iRSlk3UKu_kRvPgF_STmMefw5qUEwi-F_N_h_0DoLJUqj-oaAmkjHWMhZJAZR9lEKUIZhtI55bbAuduLWndw9RA-zNXC-P4Qswc3KxlOX1sBtw_Sc1JOGIjA8Bw5J4zYWvIliCi3wknh5jfoosK3kBJhYK37tL2Pzeb5c8CcDZr3U52huVxHa1MPETc8STfQgio30bKfGTnZQp-9r_ePx-dJPqwmPo8NDzU2bhzuN277Zq85vDdfiquX4klh14ehKHE6xo2qZIzgtJRuCQwXFS5Ko5_elDQLjzDYRvOC4qxw9S41_FaMXivsBpDUHHjkx9dP_9zuGES0je4uLwbNVjCdrRDkEFMS0CyWzA7HzOpcMsbSKMqFljzjuQLbtI3HIagwFZylPNTCojLKlLlQpSIZsx20WA5LtYcwjwXRVIICrUHHOiU6jiAkGRCjLGK9j3b9vSYvvoFGwgQAMF7fR57Cs42fiMRSJrGUSRxlkm676xYH_wWcopXWoNtJOu3e9SFapcYj8dmKR2hxPHpVx8ajGGcnjmW-Aboewes |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1JT8JAFJ4YjcaLcRfXOXikhlnamR4JQkCBEBHjrWk7M6bRFEKBhJs_wYt_0F_iLKDEm5dmkslrk3l7573vAXAdC5kGFUU9YTId7SGEl-hAWWcpXGqBUilmpsG50w2aA3r37C-rCU0vjMOH-PnhZjTD2muj4COhVpQcEco9LXLoBhFkWsk37JWfAXemvd-cC3OHIMV9zzj3BbqPKeb584IVF7Qaplo_09gFO4sAEVYdR_fAmsz3waYbGTk_AJ_dr_ePl7d5OizmrowNDhXUURzsVx_6eq82fNJPDItR9iqhhWHIchhPYLXICUEwzoVdUgKzAma5Nk8zKfTCUWjaaq2OYZLZdpcynGXjaQHt_JGyJR676fWLL7famiI4BING_bHW9BajFbyUhhh5OAkFMbMxkwoThJA4CFKuBEtYKqnBbGOhT6Ufc0Zi5ituqBJMpD5QKQMRkiOwng9zeQIgCzlSWFBJlaIqVDFSYUB9lFCkbUWoSuDYnWs0cvgZEeGUUsIqJeAY_LOxTEgMZyLDmchyJuq0OnZx-l-CK7DVu21E7Vb3_gxsYx2PuFrFc7A-GU_lhY4nJsmllZhvyR3BHQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=N%E2%80%90glycosylation+of+the+SARS%E2%80%90CoV%E2%80%902+spike+protein+at+Asn331+and+Asn343+is+involved+in+spike%E2%80%90ACE2+binding%2C+virus+entry%2C+and+regulation+of+IL%E2%80%906&rft.jtitle=Microbiology+and+immunology&rft.au=Das%2C+Tuhin&rft.au=Luo%2C+Shuhong&rft.au=Tang%2C+Hao&rft.au=Fang%2C+Jianmin&rft.date=2024-05-01&rft.issn=0385-5600&rft.eissn=1348-0421&rft.volume=68&rft.issue=5&rft.spage=165&rft.epage=178&rft_id=info:doi/10.1111%2F1348-0421.13121&rft.externalDBID=10.1111%252F1348-0421.13121&rft.externalDocID=MIM13121 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0385-5600&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0385-5600&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0385-5600&client=summon |